| Nov 7 |
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
|
| Nov 7 |
Gilead increases 2024 outlook, expects new drug filing by end of year
|
| Nov 7 |
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook
|
| Nov 7 |
Q3 2024 Gilead Sciences Inc Earnings Call
|
| Nov 7 |
Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
|
| Nov 7 |
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
|
| Nov 7 |
Gilead Sciences declares $0.77 dividend
|
| Nov 7 |
Gilead Sciences Inc (GILD) Q3 2024 Earnings Call Highlights: Strong HIV and Oncology Sales ...
|
| Nov 7 |
Gilead Sciences, Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Nov 7 |
Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript
|
